ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.
American journal of translational research(2023)
摘要
c-Met overexpression and activation is an essential mechanism of sorafenib resistance in HCC. Combination therapy of sorafenib plus c-Met inhibitor overcame the resistance of sorafenib-targeted therapy for HCC.
更多查看译文
关键词
ETS-1,Hepatocellular carcinoma,c-Met,sorafenib,sorafenib resistance
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要